Disclaimer: Information contained in the MDF web site is purely for informational and education purposes only. It is not intended to replace, and should not be interpreted or relied upon as professional advice. MDF makes no express or implied warranties or representations of any kind regarding any of the information transmitted to or received by any individual/entity in connection with such individual/entity’s use of the MDF web site. Such information should not be regarded as endorsed nor recommended by the MDF or persons responsible for the web site. The user assumes the entire risk as to the accuracy and the use of this document. By accessing the MDF web site, you agree to the terms and conditions contained in this disclaimer.

Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive–Compulsive Disorder
Using a questionnaire-based study, we assessed the parentreported prevalence of attention-deficit hyperactivity disorders (ADHDs), autism spectrum disorders, and obsessive–compulsive disorders in a group of 351 males with Duchenne muscular dystrophy. Of the 351 males with Duchenne muscular dystrophy, 11.7% were reported to have a comorbid diagnosis of ADHD, 3.1% had autism spectrum disorder, and 4.8% had obsessive–compulsive disorder. It can be concluded that the incidence of these neuropsychiatric disorders is higher in Duchenne males than in the normal population. This finding,
together with recent reports on the higher prevalence of cognitive and learning problems in Duchenne, supports the view that Duchenne muscular dystrophy is not only a muscular disorder but also a disorder affecting the brain. It is important for clinical practice to take in account this heightened association. More research is needed to examine this association and its consequences.. Read more... (PDF 66Kb)     
New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials
Muscular dystrophies primarily affect skeletal muscle. Mutations in a large number of genes, mainly encoding cytoskeletal proteins, cause different forms of dystrophy that compromise patient mobility and quality of life, and in the most severe cases lead to complete paralysis and premature death. Although muscular dystrophies still lack an effective therapy, several novel strategies are entering or are ready to enter clinical trials. Here we review the main experimental strategies, namely drug, gene and cell therapies, outlining their goals and limitations. We also provide an update of ongoing or planned clinical trials based on these strategies. Read more... (PDF 324Kb)
       

 

More >>